Home » Stocks » ANVS

Annovis Bio, Inc. (ANVS)

Stock Price: $4.56 USD -0.32 (-6.56%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 31.31M
Revenue (ttm) n/a
Net Income (ttm) -3.21M
Shares Out 6.87M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $4.56
Previous Close $4.88
Change ($) -0.32
Change (%) -6.56%
Day's Open 4.86
Day's Range 4.55 - 4.85
Day's Volume 30,395
52-Week Range 2.42 - 10.61

More Stats

Market Cap 31.31M
Enterprise Value 21.55M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 6.87M
Float 4.07M
EPS (basic) n/a
EPS (diluted) -0.47
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 31,769
Short Ratio 1.16
Short % of Float 0.78%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.51
Revenue n/a
Operating Income n/a
Net Income -3.21M
Free Cash Flow n/a
Net Cash 9.76M
Net Cash / Share 1.42
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -50.46%
ROE -75.85%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $4.56
Target: 12.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-1.61-0.71
Net Income-0.99-0.71
Shares Outstanding0.280.28
Earnings Per Share-3.51-2.57
Operating Cash Flow-0.48-0.56
Free Cash Flow-0.48-0.56
Cash & Equivalents0.000.04
Total Debt0.50-
Net Cash / Debt-0.500.04
Book Value-8.58-7.59
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Annovis Bio, Inc.
Country United States
Employees 2
CEO Maria-Luisa Maccecchini

Stock Information

Ticker Symbol ANVS
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: ANVS
IPO Date January 29, 2020


Annovis Bio, a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.